We review and compare the best options from Hims, Bluechew ... is as simple or simpler than taking a pill. All you’ll do is chew and swallow. Be sure to keep chewable ED medications out of ...

Hims & Hers Health is a top growth stock with strong cash flow, no debt, and an innovative AI-powered platform. Learn more on ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing hair-loss treatments to young men without adequately flagging up some ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular weight-loss drugs today. Additionally, the FDA last week hindered the ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Hims & Hers is shutting down the dermatology business it acquired four years ago, Business Insider has learned. On Friday, the telehealth company discontinued Apostrophe, the direct-to-consumer ...

(staged scene) Photo: Roberto Pfeil/dpa (Photo by Roberto Pfeil/picture alliance via Getty Images) Hims & Hers Health (NYSE:HIMS) stock might surge. However, there’s significant risk. HIMS stock ...

Hims & Hers Health Inc (NYSE:HIMS) stock has had a roller coaster week. The shares gapped higher by 17.5% on Tuesday despite a downgrade, unironically, to "equal-weight" from "overweight" at ...